"Myositis, Inclusion Body" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)
MeSH Number(s)
C05.651.594.600
C10.668.491.562.500
Concept/Terms
Myositis, Inclusion Body- Myositis, Inclusion Body
- Inclusion Body Myositides
- Myositides, Inclusion Body
- Inclusion Body Myositis
Inclusion Body Myopathy, Sporadic- Inclusion Body Myopathy, Sporadic
- Myositis, Inclusion Body, Sporadic
- Myopathy, Inclusion Body, Sporadic
- Inclusion Body Myositis, Sporadic
- Sporadic Inclusion Body Myositis
Below are MeSH descriptors whose meaning is more general than "Myositis, Inclusion Body".
Below are MeSH descriptors whose meaning is more specific than "Myositis, Inclusion Body".
This graph shows the total number of publications written about "Myositis, Inclusion Body" by people in Harvard Catalyst Profiles by year, and whether "Myositis, Inclusion Body" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 2 | 0 | 2 |
1997 | 2 | 0 | 2 |
1998 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2003 | 0 | 2 | 2 |
2004 | 1 | 0 | 1 |
2005 | 2 | 2 | 4 |
2006 | 2 | 0 | 2 |
2007 | 5 | 0 | 5 |
2008 | 2 | 1 | 3 |
2009 | 8 | 1 | 9 |
2010 | 2 | 2 | 4 |
2011 | 4 | 0 | 4 |
2012 | 2 | 0 | 2 |
2013 | 5 | 0 | 5 |
2014 | 6 | 1 | 7 |
2016 | 4 | 1 | 5 |
2017 | 3 | 0 | 3 |
2018 | 1 | 0 | 1 |
2019 | 6 | 1 | 7 |
2020 | 3 | 0 | 3 |
2021 | 2 | 0 | 2 |
2022 | 5 | 0 | 5 |
2023 | 2 | 0 | 2 |
Below are the most recent publications written about "Myositis, Inclusion Body" by people in Profiles.
-
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 10; 22(10):900-911.
-
Imaging With PET/CT of Diffuse CD8 T-Cell Infiltration of Skeletal Muscle in Patients With Inclusion Body Myositis. Neurology. 2023 09 12; 101(11):e1158-e1166.
-
Pseudoacute Presentation of Inclusion Body Myositis After COVID-19 Infection. J Clin Neuromuscul Dis. 2022 12 01; 24(2):111-112.
-
Inclusion Body Myositis: Boundaries That May Define Transition to Treatment Refractoriness. Neurology. 2022 Nov 15; 99(20):873-874.
-
Correlations of disease severity outcome measures in inclusion body myositis. Neuromuscul Disord. 2022 10; 32(10):800-805.
-
Quantitative MRI Biomarkers as Potential Inclusion Body Myositis Clinical Trial Endpoints. Neurology. 2022 08 30; 99(9):361-362.
-
Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells. Neurology. 2022 03 29; 98(13):e1374-e1383.
-
Counting People With Inclusion Body Myositis. Neurology. 2021 05 25; 96(21):977-979.
-
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 03 23; 96(12):e1595-e1607.
-
Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. PLoS One. 2020; 15(12):e0231064.